ChiCTR2000033520 版本V1.0 版本创建时间2020/06/03 22:45:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000033520 

最近更新日期:

Date of Last Refreshed on:

2020-06-03 22:44:25 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

待编辑(三)不同剂量纳美芬复合盐酸氢吗啡酮用于结直肠癌术后镇痛的临床观察

Public title:

Clinical observation of different doses of nalmefene combined with hydromorphone on postoperative analgesia following colorectal cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同剂量纳美芬复合盐酸氢吗啡酮用于结直肠癌术后镇痛的临床观察

Scientific title:

Clinical observation of different doses of nalmefene combined with hydromorphone on postoperative analgesia following colorectal cancer surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王晔 

研究负责人:

郭正纲 

Applicant:

Ye Wang 

Study leader:

Zhenggang Guo 

申请注册联系人电话:

Applicant telephone:

13810386807

研究负责人电话:

Study leader's telephone:

13581918132

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

shougangwangye@163.com

研究负责人电子邮件:

Study leader's E-mail:

shouganggzg@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市石景山区晋元庄路9号

研究负责人通讯地址:

北京市石景山区晋元庄路9号

Applicant address:

9 Jinyuan Zhuang Road, Shijingshan District, Beijing

Study leader's address:

9 Jinyuan Zhuang Road, Shijingshan District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学首钢医院

Applicant's institution:

Peking University Shougang Hospital

研究负责人所在单位:

北京大学首钢医院

Affiliation of the Leader:

Peking University Shougang Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学首钢医院

Primary sponsor:

Peking University Shougang Hospital

研究实施负责(组长)单位地址:

北京市石景山区晋元庄路9号

Primary sponsor's address:

9 Jinyuan Zhuang Road, Shijingshan District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学首钢医院

具体地址:

石景山区晋元庄路9号

Institution
hospital:

Peking University Shougang Hospital

Address:

9 Jinyuanzhuang Road, Shijingshan District

经费或物资来源:

自筹经费

Source(s) of funding:

Self-financing

Target disease:

Colorectal cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

不同剂量对照 

Study design:

Dose comparison 

研究目的:

观察不同剂量纳美芬对于盐酸氢吗啡酮术后镇痛的效果及其不良反应的影响。  

Objectives of Study:

To evaluat the efficacy of different doses of nalmefene on pain intensity and side effect in patients receiving patient-controlled analgesia (PCA) with hydromorphone.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄18~65岁;18<BMI<30;ASA Ⅰ~Ⅲ级;择期行结直肠癌根治术;术前已签署知情同意书并自愿加入本研究。

Inclusion criteria

Age ≤65 years and age ≥18, 18<BMI<30, ASA I–III, Selective radical operation with colorectal cancer, Willing participants and signed informed consent.

排除标准:

术前恶心、呕吐,皮肤病史;严重肝肾功能障碍及其它重要脏器疾病史;神经精神类疾病史;酒精或阿片类药物滥用史;相关药物过敏史;不能正确读取或识别VAS评分及Ramsay分级(语言障碍等);术前24小时内曾应用阿片类药物、止吐、止痒剂,术前15天曾应用抗抑郁药或单胺氧化酶抑制剂;术后需进入ICU继续治疗者。

Exclusion criteria:

History of nausea and vomiting, skin disease, or remarkably abnormal liver and/or kidney function, or mental illness, or alcohol drug abuse, or allergy to related opioid drugs, or inability to understand or describe VAS score or Ramsay Sedation classification(e.g. language barrier), or opioids, antiemetic drugs and antipruritic drugs use within 24h prior to the operation, or antidepressant or monoamine oxidase inhibitor (MAOI) use 15 days before surgery, or transfer to intensive care unit (ICU) after surgery.

研究实施时间:

Study execute time:

From 2020-07-01 00:00:00 To 2021-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-07-01 00:00:00 To 2021-02-28 00:00:00  

干预措施:

Interventions:

组别:

低剂量组

样本量:

30

Group:

Low dose Group

Sample size:

干预措施:

盐酸氢吗啡酮0.1mg/kg +纳美芬2μg/kg +生理盐水共100ml

干预措施代码:

L

Intervention:

hydromorphone 0.1mg/kg +nalmefene 3μg/kg +normal saline to 100ml

Intervention code:

组别:

极低剂量组

样本量:

30

Group:

Ultra Low Dose Group

Sample size:

干预措施:

盐酸氢吗啡酮0.1mg/kg +纳美芬0.5μg/kg +生理盐水共100ml

干预措施代码:

U

Intervention:

hydromorphone 0.1mg/kg +nalmefene 1μg/kg +normal saline to 100ml

Intervention code:

组别:

对照组

样本量:

30

Group:

Control Group

Sample size:

干预措施:

盐酸氢吗啡酮0.1mg/kg +生理盐水共100ml

干预措施代码:

C

Intervention:

hydromorphone 0.1mg/kg +normal saline to 100ml

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学首钢医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Shougang Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后疼痛程度

指标类型:

主要指标

Outcome:

Postoperative pain intensity

Type:

Primary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

视觉模拟评分法

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

VAS Score

指标中文名:

镇痛泵按压次数

指标类型:

次要指标

Outcome:

Bolus frequency

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

读取数值

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

read values

指标中文名:

补救镇痛药剂量

指标类型:

次要指标

Outcome:

analgesic rescue

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

镇静分级

指标类型:

次要指标

Outcome:

Level of sedation

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Ramsay镇静分级

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

Ramsay sedation score

指标中文名:

恶心

指标类型:

次要指标

Outcome:

nausea

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

呕吐

指标类型:

次要指标

Outcome:

vomiting

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

呕吐药补救

指标类型:

次要指标

Outcome:

antiemetic rescue

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

瘙痒

指标类型:

次要指标

Outcome:

pruritus

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

呼吸抑制

指标类型:

次要指标

Outcome:

Respiratory depression

Type:

Secondary indicator

测量时间点:

术后1,6,12,24,48小时

测量方法:

Measure time point of outcome:

at the time of 1h, 6h, 12h, 24h, 48h after surgery

Measure method:

指标中文名:

排气时间

指标类型:

次要指标

Outcome:

Time to gastrointestinal recovery

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

After surgery

Measure method:

指标中文名:

下地活动时间

指标类型:

次要指标

Outcome:

Time to out-of-bed activity

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

After surgery

Measure method:

指标中文名:

引流管拔管时间

指标类型:

次要指标

Outcome:

Time to drainage tube removal

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

After surgery

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

The duration of hospital stay

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

After surgery

Measure method:

指标中文名:

患者对于术后镇痛满意度

指标类型:

次要指标

Outcome:

The degree of satisfaction with their pain management experience

Type:

Secondary indicator

测量时间点:

术后48小时

测量方法:

Measure time point of outcome:

at the time of 48h after surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

SPSS

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本试验为随机对照双盲研究。

Blinding:

The study is a double-blind randomized controlled study.

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-06-03 22:44:25